---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-064516"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:19:42.836255+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# INmune Bio Q2 net loss $6.5M; XPro™ AD trial enrolling; INKmune™ IND cleared

## Summary
- Net loss $6.5M vs $6.8M YoY; R&D $4.1M; G&A $2.3M; cash $47.8M at June 30, 2023.
- XPro™ Phase II Early AD trial enrolling; FDA pathway to lift clinical hold before end-2023.
- New MRI gray matter biomarker data from XPro™ presented at AAIC July 2023.
- INKmune™ IND cleared for Phase I/II in mCRPC; first patient enrollment expected Q4 2023.
- Top-line XPro™ AD results anticipated late 2024; LAUREL trial opened third site in Greece.

## SEC filing metadata
- accession: 0001213900-23-064516
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390023064516/0001213900-23-064516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390023064516/ea183062-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-064516
- JSON: https://secwatch.observer/filing/0001213900-23-064516.json
- Plain text: https://secwatch.observer/filing/0001213900-23-064516.txt

## Key facts
- Earnings Releases
  Inmune Bio, Inc. reported financial results for quarter ended June 30, 2023.
  - Period: quarter ended June 30, 2023
  - Result: reported results
  source text: On August 7, 2023, INmune Bio Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390023064516/0001213900-23-064516-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.